In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The role of biomarkers in risk stratification of kidney injury in patients with acute coronary syndrome

Session Poster Session 2

Speaker Associate Professor Irina Vishnevskaya

Event : Heart Failure 2016

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Renal Failure and Cardiovascular Disease
  • Session type : Poster Session

Authors : IR Vyshnevska (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), OV Petyunina (Kharkiv,UA), NV Tytarenko (Kharkiv,UA), NV Bila (Kharkiv,UA)

IR Vyshnevska1 , MP Kopytsya1 , OV Petyunina1 , NV Tytarenko1 , NV Bila1 , 1Government institution'L.T. Malaya Therapy National institute of the National academy of medical sci - Kharkiv - Ukraine ,

European Journal of Heart Failure Abstracts Supplement ( 2016 ) 18 ( Supplement 1 ), 278

The development of renal dysfunction in patient with acute myocardial infarction, especially in those who underwent angiography, is an actual problem, because it worsens the prognosis for those patients. In order to diagnose this condition in time the search for biomarkers is going. One of them is the Growth differentiation factor 15 (GDF 15). Purpose: estimate the role of various markers in the development of cardiorenal syndrome in patients with acute coronary syndrome (ACS). Methods: 73 patients were screened with different forms of ACS (55 male and 18 female), mean age was 61, 8 ± 1, 3 years. In anamnesis patients had: 23% - previous myocardial infarction, 51% - stable angina, 84% - hypertension, 16% - diabetes mellitus, 6 % - chronic kidney disease. Based on the results of the examination glomerular filtration rate (GFR) was calculated by Modified diet renal disease method (MDRD). A group of patients has been selected (n = 54), their creatinine level was determined during the first 24 hours and after 48 hours. All patients were divided into two groups according to acute kidney injury network classification (AKIN): 21 patient in the first group with negative dynamic (1st stage AKIN and higher), 33 patient in the second group without creatinine dynamic. In addition, the levels of GDF 15, N terminal-pro B-type natriuretic peptide (NT-pro BNP) were determined during the first day of hospitalization (normal range of GDF 15 <1200 pg / ml, NT pro-BNP <200 ng/ml). The follow-up period was 6 months. Results: By comparing selected groups significant difference was found in creatinine level and GFR in both groups ( < 0.001;  < 0.01, respectively). The analyses of biomarkers interconnection (NT pro-BNP, GDF 15) and GFR showed significant difference of estimated parameters in both groups as well ( ≤ 0.04; ≤ 0.02, respectively). Also, correlation of high and medium strength was found between biomarkers (GDF 15, NT pro-BNP) and GFR ( ≤ 0.0001, p≤0.01). Conclusions: The biomarker GDF 15 can be used for risk stratification in development of acute kidney injury in patients with ACS, its as sensitive as the known marker NT- pro BNP. For high prognostic possibility we can use combination of biomarkers.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are